MCID: BNM001
MIFTS: 51

Bone Marrow Cancer malady

Categories: Cancer diseases, Immune diseases, Blood diseases, Bone diseases

Aliases & Classifications for Bone Marrow Cancer

Aliases & Descriptions for Bone Marrow Cancer:

Name: Bone Marrow Cancer 12 14
Malignant Neoplasm of Bone Marrow 12 69
Myeloproliferative Disorders 42
Malignant Bone Marrow Tumor 12
Myeloproliferative Disease 69
Bone Marrow Neoplasms 69
Bone Marrow Neoplasm 12
Bone Marrow Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4960
ICD10 33 D47.1
MeSH 42 D009196
UMLS 69 C0027022

Summaries for Bone Marrow Cancer

Disease Ontology : 12 A hematopoietic cancer that derives from the blood-forming stem cells of the bone marrow.

MalaCards based summary : Bone Marrow Cancer, also known as malignant neoplasm of bone marrow, is related to myeloproliferative neoplasm and myeloproliferative disorder with eosinophilia. An important gene associated with Bone Marrow Cancer is JAK2 (Janus Kinase 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Lenograstim and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include bone and bone marrow, and related phenotypes are Decreased viability and hematopoietic system

Related Diseases for Bone Marrow Cancer

Diseases related to Bone Marrow Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 102)
id Related Disease Score Top Affiliating Genes
1 myeloproliferative neoplasm 32.9 CSF3 JAK2 MPL RUNX1 THPO
2 myeloproliferative disorder with eosinophilia 12.3
3 essential thrombocythemia 11.2
4 pdgfrb-associated chronic eosinophilic leukemia 11.1
5 budd-chiari syndrome 11.0
6 erythromelalgia 11.0
7 campomelic dysplasia 10.8
8 myelofibrosis with myeloid metaplasia, somatic 10.8
9 leukemia, acute myelomonocytic, somatic, somatic 10.8
10 thrombocythemia 1 10.8
11 polycythemia vera, somatic 10.8
12 leukemia, chronic myeloid, somatic 10.8
13 myelodysplastic syndrome 10.8
14 myelofibrosis 10.8
15 ocular cancer 10.8
16 papular mucinosis 10.8
17 noonan syndrome 6 10.6
18 noonan syndrome 8 10.6
19 noonan syndrome 4 10.6
20 erythermalgia, primary 10.6
21 noonan syndrome 5 10.6
22 noonan syndrome 7 10.6
23 chromosome 8p11 myeloproliferative syndrome 10.6
24 thrombocythemia 3 10.6
25 noonan syndrome 3 10.6
26 noonan syndrome 1 10.6
27 noonan syndrome 9 10.6
28 noonan syndrome 10 10.6
29 myelodysplastic myeloproliferative cancer 10.6
30 down syndrome 10.5
31 leukemia 10.5
32 thrombocytopenia, congenital amegakaryocytic 10.3 IL3 MPL THPO
33 spondylocostal dysostosis 2 10.3 EPO JAK2 MPL
34 acute respiratory distress syndrome 10.3 FLT3 JAK2 KIT
35 thrombosis 10.3
36 long qt syndrome 10.3 EPO EPOR JAK2
37 agammaglobulinemia 8, autosomal dominant 10.3 FLT3 JAK2 KIT
38 necrotic uveal melanoma 10.3 FLT3 GATA1 PTPN11
39 pyloric stenosis, infantile hypertrophic, 4 10.3 EPO GATA1 IL3 JAK2
40 unilateral hemispheric polymicrogyria 10.3 FLT3 KIT RUNX1
41 pigmented purpuric dermatosis 10.3 ABL1 BCR
42 autosomal dominant proximal renal tubular acidosis 10.3 FGFR1 PDGFRA PDGFRB
43 acute liver failure 10.3 EPO EPOR GATA1 JAK2
44 comt-related pain sensitivity alteration 10.3 BCR EPO RUNX1
45 dfnb1 10.3 KIT PDGFRA PDGFRB
46 myeloid and lymphoid neoplasms associated with fgfr1 abnormalities 10.3 FGFR1 JAK2 PDGFRA PDGFRB
47 queensland tick typhus 10.3 EPO EPOR IL3 JAK2
48 adducted thumbs dundar type 10.3 FLT3 KIT RUNX1
49 ocular hyperemia 10.3 CSF3 JAK2 MPL THPO
50 craniofrontonasal dysplasia 10.3 GATA1 THPO

Graphical network of the top 20 diseases related to Bone Marrow Cancer:



Diseases related to Bone Marrow Cancer

Symptoms & Phenotypes for Bone Marrow Cancer

GenomeRNAi Phenotypes related to Bone Marrow Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 9.98 FLT3 PDGFRA
2 Decreased viability GR00221-A-1 9.98 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
3 Decreased viability GR00221-A-2 9.98 ABL1 FGFR1
4 Decreased viability GR00221-A-3 9.98 ABL1 PDGFRA PDGFRB
5 Decreased viability GR00221-A-4 9.98 FLT3 PDGFRA PDGFRB
6 Decreased viability GR00301-A 9.98 KIT
7 Decreased viability GR00342-S-1 9.98 ABL1 PDGFRB
8 Decreased viability GR00342-S-2 9.98 ABL1
9 Decreased viability GR00342-S-3 9.98 ABL1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.88 ABL1 BCR FGFR1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.88 ABL1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.88 CSF3
13 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.88 BCR
14 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.88 BCR
15 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.88 ABL1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.88 BCR
17 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.88 FGFR1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.88 FGFR1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.88 ABL1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.88 ABL1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.88 BCR
22 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.88 BCR
23 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.88 FGFR1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.88 FGFR1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-2 9.88 BCR
26 Increased shRNA abundance (Z-score > 2) GR00366-A-215 9.88 BCR
27 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.88 BCR
28 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.88 ABL1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.88 ABL1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.88 FGFR1 ABL1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-45 9.88 CSF3
32 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.88 ABL1 FGFR1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.88 FGFR1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-6 9.88 CSF3
35 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.88 FGFR1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.88 ABL1 BCR FGFR1 CSF3
37 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.88 ABL1 BCR
38 Decreased substrate adherent cell growth GR00193-A-1 9.7 KIT
39 Decreased substrate adherent cell growth GR00193-A-2 9.7 KIT ABL1
40 Decreased substrate adherent cell growth GR00193-A-4 9.7 ABL1 FGFR1 FLT3 KIT

MGI Mouse Phenotypes related to Bone Marrow Cancer:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.43 MPL PDGFRA PDGFRB PTPN11 RUNX1 STAT5A
2 cellular MP:0005384 10.42 ABL1 BCR EPO EPOR FGFR1 FLT3
3 immune system MP:0005387 10.39 ABL1 BCR CD177 CSF3 EPO EPOR
4 homeostasis/metabolism MP:0005376 10.36 MPL PDGFRA PDGFRB PTPN11 RUNX1 STAT5A
5 growth/size/body region MP:0005378 10.34 ABL1 BCR EPOR FGFR1 FLT3 GATA1
6 embryo MP:0005380 10.3 PDGFRA PDGFRB PTPN11 RUNX1 ABL1 EPO
7 cardiovascular system MP:0005385 10.26 ABL1 EPO EPOR FGFR1 GATA1 KIT
8 mortality/aging MP:0010768 10.22 ABL1 BCR EPO EPOR FGFR1 FLT3
9 endocrine/exocrine gland MP:0005379 10.21 ABL1 FGFR1 FLT3 JAK2 KIT PDGFRA
10 integument MP:0010771 10.14 PTPN11 RUNX1 STAT5A CSF3 EPO FGFR1
11 digestive/alimentary MP:0005381 10.08 ABL1 BCR FGFR1 KIT PDGFRA PDGFRB
12 liver/biliary system MP:0005370 10.07 ABL1 BCR EPO EPOR GATA1 JAK2
13 normal MP:0002873 9.97 FGFR1 GATA1 JAK2 KIT PDGFRA PDGFRB
14 no phenotypic analysis MP:0003012 9.8 EPOR FGFR1 FLT3 KIT PDGFRA PTPN11
15 respiratory system MP:0005388 9.56 ABL1 EPO EPOR GATA1 KIT PDGFRA
16 skeleton MP:0005390 9.36 ABL1 EPO FGFR1 FLT3 GATA1 JAK2

Drugs & Therapeutics for Bone Marrow Cancer

Drugs for Bone Marrow Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 862)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
2
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
3
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
5
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128794-94-5 5281078
6
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
8
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
9
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
10
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 104987-11-3 445643 439492
11
Azacitidine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 320-67-2 9444
12
Decitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2353-33-5 451668
13
Zoledronic acid Approved Phase 4,Phase 2,Phase 3,Phase 1 118072-93-8 68740
14
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
15
Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 52-24-4 5453
16
Bleomycin Approved Phase 4,Phase 3,Phase 1,Phase 2 11056-06-7 5360373
17
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
18
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
19
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 179324-69-7 387447 93860
20
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-02-2 5743
21
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
22
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 21679-14-1, 75607-67-9 30751
23
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58957-92-9 42890
24
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 55-98-1 2478
25
Vidarabine Approved Phase 4,Phase 2,Phase 3,Phase 1 24356-66-9 32326 21704
26
Asparaginase Approved Phase 4,Phase 2,Phase 3,Phase 1 9015-68-3
27
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 20830-81-3 30323
28
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
29
Dasatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 302962-49-8 3062316
30
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
31
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
32
Iron Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 7439-89-6 23925
33
Hydroxyurea Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 127-07-1 3657
34
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
35
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 5754 657311
36
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 65271-80-9 4212
37
Teniposide Approved Phase 4,Phase 2 29767-20-2 34698
38
Mechlorethamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-75-2 4033
39
Methoxyflurane Approved, Vet_approved Phase 4 76-38-0 4116
40
Lamivudine Approved, Investigational Phase 4,Phase 1,Phase 2 134678-17-4 60825
41
Nevirapine Approved Phase 4 129618-40-2 4463
42
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
43
Eszopiclone Approved Phase 4 138729-47-2 969472
44
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 2 170729-80-3 151165 6918365
45
Fosaprepitant Approved Phase 4,Phase 3,Phase 2 172673-20-0 219090
46
Ondansetron Approved Phase 4,Phase 3,Phase 2,Phase 1 99614-02-5 4595
47
Zinc Approved Phase 4,Phase 2,Phase 3 7440-66-6 32051 23994
48
Piperacillin Approved Phase 4,Phase 3 66258-76-2 43672
49
Tazobactam Approved Phase 4,Phase 3 89786-04-9 123630
50
Deferasirox Approved, Investigational Phase 4,Phase 3,Phase 2 201530-41-8 5493381

Interventional clinical trials:

(show top 50) (show all 4404)
id Name Status NCT ID Phase
1 Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer Unknown status NCT00030758 Phase 4
2 Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant Unknown status NCT02084446 Phase 4
3 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4
4 A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome Unknown status NCT02013102 Phase 4
5 Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation Unknown status NCT01243489 Phase 4
6 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4
7 Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer Completed NCT00219271 Phase 4
8 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
9 A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation Completed NCT00067730 Phase 4
10 Safety and Efficacy of Methoxyflurane for Treatment of Incident Pain Completed NCT00524927 Phase 4
11 HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT Completed NCT00380770 Phase 4
12 Effect of Eszopiclone on Sleep Disturbance and Pain in Cancer Completed NCT00365261 Phase 4
13 A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma Completed NCT02268890 Phase 4
14 Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients Completed NCT01129336 Phase 4
15 Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis Completed NCT00241111 Phase 4
16 Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis Completed NCT00237159 Phase 4
17 Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor Completed NCT01362985 Phase 4
18 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4
19 Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates Completed NCT00765687 Phase 4
20 Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer Completed NCT00334139 Phase 4
21 Odansetron and Dexamethasone Alone vs. Odansetron, Dexamethason and Apreptant to Prevent Nausea Completed NCT00781768 Phase 4
22 Oral Zinc Therapy for the Prevention of Mucositis Completed NCT00449592 Phase 4
23 Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation Completed NCT01339572 Phase 4
24 SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia Completed NCT00487448 Phase 4
25 Imatinib in KIT-negative Systemic Mastocytosis Completed NCT01297777 Phase 4
26 An Observational Study of Chinese Multiple Myeloma Patients Treated With Velcade Completed NCT01675245 Phase 4
27 Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Completed NCT00361140 Phase 4
28 Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) Completed NCT01201811 Phase 4
29 LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia Completed NCT00526409 Phase 4
30 Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4
31 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4
32 Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients Completed NCT00195533 Phase 4
33 A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4
34 An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment Completed NCT00980018 Phase 4
35 CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib Completed NCT01227577 Phase 4
36 Glivec in Pediatric Chronic Myeloid Leukemia (CML) Completed NCT00845221 Phase 4
37 Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4
38 Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Completed NCT00081926 Phase 4
39 Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4
40 Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery Completed NCT00357656 Phase 4
41 An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome Completed NCT01400633 Phase 4
42 A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome Completed NCT01041846 Phase 4
43 Survey on QUality of Life In myeloDisplasia (SQUID) Completed NCT00967564 Phase 4
44 Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome Completed NCT00488436 Phase 4
45 Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial Completed NCT01368523 Phase 4
46 Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response Completed NCT01043874 Phase 4
47 Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Completed NCT00786812 Phase 4
48 Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) Completed NCT00171899 Phase 4
49 Tasigna in Glivec-resistant or Intolerant Patients in CML Completed NCT01206088 Phase 4
50 Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload Completed NCT00564941 Phase 4

Search NIH Clinical Center for Bone Marrow Cancer

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: myeloproliferative disorders

Genetic Tests for Bone Marrow Cancer

Anatomical Context for Bone Marrow Cancer

MalaCards organs/tissues related to Bone Marrow Cancer:

39
Bone, Bone Marrow

Publications for Bone Marrow Cancer

Articles related to Bone Marrow Cancer:

id Title Authors Year
1
Mayo breakthrough: virus may destroy bone marrow cancer. ( 25233543 )
2014
2
Erythrokinetics and androgens in bone marrow cancer. ( 975001 )
1976

Variations for Bone Marrow Cancer

ClinVar genetic disease variations for Bone Marrow Cancer:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 JAK2 NM_004972.3(JAK2): c.1849G> T (p.Val617Phe) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs77375493 GRCh37 Chromosome 9, 5073770: 5073770
2 FGFR3 NM_000142.4(FGFR3): c.1118A> G (p.Tyr373Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913485 GRCh37 Chromosome 4, 1806099: 1806099
3 INSL6; JAK2 NM_004972.3(JAK2): c.2047A> G (p.Arg683Gly) single nucleotide variant Pathogenic/Likely pathogenic rs1057519721 GRCh37 Chromosome 9, 5078360: 5078360

Expression for Bone Marrow Cancer

Search GEO for disease gene expression data for Bone Marrow Cancer.

Pathways for Bone Marrow Cancer

Pathways related to Bone Marrow Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 ABL1 CD177 CSF3 FGFR1 FLT3 IL3
2
Show member pathways
13.88 ABL1 CSF3 EPOR FGFR1 FLT3 IL3
3
Show member pathways
13.75 BCR FGFR1 JAK2 KIT PDGFRA PDGFRB
4
Show member pathways
13.75 EPOR FGFR1 FLT3 IL3 JAK2 KIT
5
Show member pathways
13.64 CSF3 EPO EPOR FGFR1 FLT3 IL3
6
Show member pathways
13.58 EPOR FGFR1 FLT3 IL3 KIT PDGFRA
7
Show member pathways
13.53 EPO EPOR FGFR1 FLT3 IL3 JAK2
8
Show member pathways
13.52 ABL1 FGFR1 IL3 JAK2 KIT PDGFRA
9
Show member pathways
13.41 CSF3 EPOR FGFR1 FLT3 IL3 JAK2
10
Show member pathways
13.38 CSF3 FGFR1 FLT3 IL3 JAK2 KIT
11
Show member pathways
13.35 EPOR FGFR1 FLT3 IL3 KIT PDGFRA
12
Show member pathways
13.34 ABL1 CD177 GATA1 IL3 JAK2 MPL
13
Show member pathways
13.33 CSF3 FGFR1 IL3 JAK2 KIT PDGFRA
14
Show member pathways
13.3 EPOR FGFR1 FLT3 IL3 KIT PDGFRA
15
Show member pathways
13.08 FGFR1 IL3 KIT PDGFRA PDGFRB THPO
16
Show member pathways
13.08 FGFR1 IL3 JAK2 KIT PDGFRA PDGFRB
17
Show member pathways
13.04 FGFR1 JAK2 KIT PDGFRA PDGFRB STAT5A
18
Show member pathways
13.01 EPOR FGFR1 FLT3 KIT PDGFRA PDGFRB
19
Show member pathways
12.92 EPO EPOR JAK2 KIT PDGFRA PDGFRB
20
Show member pathways
12.82 ABL1 EPO EPOR JAK2 STAT5A
21
Show member pathways
12.8 JAK2 MPL PTPN11 STAT5A THPO
22
Show member pathways
12.76 ABL1 FGFR1 KIT PDGFRA PDGFRB PTPN11
23
Show member pathways
12.74 FGFR1 KIT PDGFRA PDGFRB PTPN11
24 12.65 ABL1 BCR FGFR1 FLT3 KIT PDGFRA
25
Show member pathways
12.61 JAK2 PDGFRA PDGFRB PTPN11 STAT5A
26 12.59 GATA1 IL3 JAK2 KIT MPL RUNX1
27 12.51 CSF3 EPO EPOR FGFR1 IL3 JAK2
28
Show member pathways
12.41 KIT PDGFRA PDGFRB PTPN11
29
Show member pathways
12.37 FLT3 KIT RUNX1 STAT5A
30
Show member pathways
12.34 FLT3 IL3 JAK2 STAT5A
31 12.21 ABL1 JAK2 PTPN11 STAT5A
32
Show member pathways
12.21 EPO EPOR IL3 JAK2 KIT PTPN11
33
Show member pathways
12.18 BCR FGFR1 STAT5A ZMYM2
34
Show member pathways
12.15 ABL1 BCR PTPN11 RUNX1 STAT5A
35 12.12 GATA1 IL3 PDGFRB RUNX1 THPO
36 11.98 CSF3 EPO FLT3 IL3 KIT MPL
37
Show member pathways
11.94 EPO EPOR JAK2 PTPN11 STAT5A
38
Show member pathways
11.9 BCR FGFR1 STAT5A ZMYM2
39
Show member pathways
11.9 IL3 JAK2 PTPN11 STAT5A
40 11.88 ABL1 JAK2 PTPN11 STAT5A
41
Show member pathways
11.85 FGFR1 FLT3 KIT PDGFRB
42 11.84 FGFR1 PDGFRA PDGFRB
43 11.79 EPOR FGFR1 IL3 PDGFRA PDGFRB THPO
44
Show member pathways
11.79 ABL1 BCR KIT PDGFRA PDGFRB
45 11.77 JAK2 PTPN11 STAT5A
46 11.74 EPO EPOR IL3 JAK2 PTPN11 STAT5A
47 11.72 FGFR1 FLT3 KIT PDGFRA PDGFRB
48 11.71 ABL1 BCR FGFR1 FLT3 JAK2 KIT
49 11.69 CSF3 EPO EPOR FLT3 IL3 KIT
50 11.64 ABL1 PDGFRB PTPN11 STAT5A

GO Terms for Bone Marrow Cancer

Cellular components related to Bone Marrow Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein complex GO:0043234 9.02 ABL1 BCR FLT3 PDGFRA PTPN11

Biological processes related to Bone Marrow Cancer according to GeneCards Suite gene sharing:

(show all 46)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.99 ABL1 EPO PDGFRA PDGFRB PTPN11 THPO
2 brain development GO:0007420 9.98 BCR EPOR FGFR1 PTPN11
3 regulation of cell proliferation GO:0042127 9.97 ABL1 FGFR1 JAK2 KIT
4 phosphatidylinositol-mediated signaling GO:0048015 9.97 FGFR1 KIT PDGFRA PDGFRB PTPN11
5 positive regulation of cell migration GO:0030335 9.95 JAK2 KIT PDGFRA PDGFRB
6 phosphatidylinositol phosphorylation GO:0046854 9.95 FGFR1 KIT PDGFRA PDGFRB PTPN11
7 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.92 FLT3 KIT PDGFRA PDGFRB
8 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.92 ABL1 CSF3 GATA1 IL3 JAK2
9 positive regulation of MAP kinase activity GO:0043406 9.9 FGFR1 FLT3 KIT PDGFRB
10 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.89 FGFR1 KIT PDGFRA PDGFRB PTPN11
11 erythrocyte differentiation GO:0030218 9.88 EPO GATA1 JAK2 KIT
12 cytokine-mediated signaling pathway GO:0019221 9.87 CSF3 EPOR FLT3 IL3 JAK2 KIT
13 positive regulation of MAPK cascade GO:0043410 9.86 FGFR1 FLT3 KIT
14 protein autophosphorylation GO:0046777 9.86 ABL1 BCR FGFR1 FLT3 JAK2 KIT
15 hemopoiesis GO:0030097 9.85 FLT3 KIT RUNX1
16 cell chemotaxis GO:0060326 9.84 KIT PDGFRA PDGFRB
17 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.84 FLT3 KIT PDGFRA PDGFRB
18 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 EPO FLT3 IL3 JAK2 KIT
19 positive regulation of DNA replication GO:0045740 9.82 EPO IL3 PDGFRA
20 embryonic hemopoiesis GO:0035162 9.78 GATA1 IL3 KIT
21 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.76 EPO IL3 JAK2 KIT
22 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.7 JAK2 STAT5A
23 cellular response to thyroid hormone stimulus GO:0097067 9.7 GATA1 KIT
24 negative regulation of cell-cell adhesion GO:0022408 9.69 ABL1 JAK2
25 positive regulation of phosphoprotein phosphatase activity GO:0032516 9.69 JAK2 PDGFRB
26 cardiac myofibril assembly GO:0055003 9.68 PDGFRA PDGFRB
27 dendritic cell differentiation GO:0097028 9.68 FLT3 GATA1
28 positive regulation of osteoblast proliferation GO:0033690 9.68 ABL1 GATA1
29 positive regulation of phospholipase C activity GO:0010863 9.67 FGFR1 KIT PDGFRA PDGFRB
30 Bergmann glial cell differentiation GO:0060020 9.66 ABL1 PTPN11
31 retina vasculature development in camera-type eye GO:0061298 9.66 PDGFRA PDGFRB
32 negative regulation of platelet-derived growth factor receptor-beta signaling pathway GO:2000587 9.65 PDGFRA PDGFRB
33 myeloid progenitor cell differentiation GO:0002318 9.65 FLT3 KIT
34 erythropoietin-mediated signaling pathway GO:0038162 9.65 EPO EPOR KIT
35 platelet-derived growth factor receptor-beta signaling pathway